Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|12/08/2020||12/03/2020||The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber disease) patients who suffer fromgastrointestinal bleeding.||Effectiveness of Somatostatin Analogues in Patients with hereditaryhemorrhagic telangiectasia and symptomatic gastrointestinal bleeding,the SAIPAN-trial: a multicenter, randomized, open-label, parallel-group,superiority trial. - SAIPAN-trial||Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease (in specific patients with gastrointestinalbleedings);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]||Other descriptive name: OCTREOTIDE ACETATE||Radboudumc||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|
|38||Phase 3||France;Netherlands;Germany;United Kingdom;Italy|
|03/06/2019||14/05/2019||The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding.||Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup, superiority trial. - SAIPAN-trial||Hereditary hemorrhagic telangiectasia (HHT);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]||Radboudumc||NULL||Authorised-recruitment may be ongoing or finished|| Female: yes|
|October 2016||17/8/2016||Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber||An Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal Bleeding||Hereditary Hemorrhagic Telangiectasia;Gastrointestinal Hemorrhage;Anemia||Drug: Octreotide LAR||Radboud University||St. Antonius Hospital||Unknown status||18 Years||N/A||All||15||Phase 2||Netherlands|
|21/07/2016||11/07/2016||The effectiveness of the drug octreotide LAR to anemia in patients with gastrointestinal bleeding due to Rendu-Osler-Weber disease.||An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding - ROW||Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia);Therapeutic area: Diseases [C] - Digestive System Diseases [C06]||Trade Name: Sandostatin LAR 20 mg|
Product Name: Sandostatin LAR
Product Code: RVG 18236
|Radboud University Medical Center||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|
|January 1995||18/10/1999||Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia||Hereditary Hemorrhagic Telangiectasia;Ectasia||Drug: octreotide||National Center for Research Resources (NCRR)||Yale University||Completed||N/A||N/A||Both||8||Phase 2||NULL|